LXRX logo

LXRX
Lexicon Pharmaceuticals Inc

13,662
Mkt Cap
$523.29M
Volume
1.65M
52W High
$2.08
52W Low
$0.2836
PE Ratio
-4.32
LXRX Fundamentals
Price
$1.39
Prev Close
$1.44
Open
$1.44
50D MA
$1.26
Beta
1.68
Avg. Volume
2.37M
EPS (Annual)
-$0.6262
P/B
4.04
Rev/Employee
$301,757.28
Loading...
Loading...
News
all
press releases
Lexicon (LXRX) Upgraded to Buy: Here's What You Should Know
Lexicon (LXRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·3mo ago
News Placeholder
More News
News Placeholder
Lexicon Pharmaceuticals (LXRX) Q2 Earnings and Revenues Top Estimates
Lexicon (LXRX) delivered earnings and revenue surprises of +112.50% and +344.78%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings and Revenue Estimates
Supernus (SUPN) delivered earnings and revenue surprises of +93.62% and +7.34%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM
Zacks·4mo ago
News Placeholder
KURA Stock Rises More Than 15% This Past Week: Here's Why
Zacks·5mo ago
News Placeholder
TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy
Zacks·5mo ago
News Placeholder
Zoetis Stock Rises 13% in a Month: Time to Add to Your Portfolio?
Zacks·5mo ago
News Placeholder
Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success
Zacks·5mo ago
News Placeholder
JNJ's Combo Therapy Shows Strong Phase III Efficacy in Prostate Cancer
Zacks·5mo ago
News Placeholder
SNY's Rilzabrutinib Wins 4th Orphan Drug Tag for Sickle Cell Disease
Zacks·5mo ago

Latest LXRX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.